LTR Pharma (ASX:LTP) EBITDA Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. LTR Pharma's EBITDA for the six months ended in Jun. 2023 was A$-1.46 Mil. LTR Pharma's Revenue for the six months ended in Jun. 2023 was A$0.00 Mil. Therefore, LTR Pharma's EBITDA margin for the quarter that ended in Jun. 2023 was 0.00%.

LTR Pharma EBITDA Margin % Historical Data

The historical data trend for LTR Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma EBITDA Margin % Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

EBITDA Margin %

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
EBITDA Margin %	-	-	-

Competitive Comparison of LTR Pharma's EBITDA Margin %

For the Biotechnology subindustry, LTR Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's EBITDA Margin % falls into.

LTR Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

LTR Pharma's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-1.455	/	0
	=	%

LTR Pharma's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.455	/	0
	=	%

LTR Pharma (ASX:LTP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

LTR Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of LTR Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines